Pipeline Expansion Leverage NovoCure's growing international sales and new launches like Optune Pax to target oncology centers expanding treatment options for glioblastoma, pancreatic cancer, and lung cancers, offering integrated support and training.

Strategic Partnerships Identify collaboration opportunities with pharma and device distributors in key markets (Japan, Europe, US) to accelerate adoption of Optune Pax and other Tumor Treating Fields therapies through co-marketing and bundled solutions.

Clinical Footprint Position offerings around ongoing and upcoming TTFields trials to engage research institutions and hospital networks seeking access to innovative modalities, with clinician education and patient outcome data support.

Cost-Effectiveness Highlight potential cost-per-life-year improvements and long-term reimbursement opportunities to hospital and payer stakeholders, aligning with NovoCure's growth trajectory and profitability targets.

Global Reach Capitalize on NovoCure’s distributed HQs and manufacturing footprint by proposing regional pilots in high-need geographies, backed by local field teams, service hubs, and regulatory navigation support.